Literature DB >> 2965792

Localization of the binding site for the human high-affinity Fc receptor on IgG.

A R Duncan1, J M Woof, L J Partridge, D R Burton, G Winter.   

Abstract

A major pathway in the clearance of pathogens involves the coating of the pathogen with specific antibodies, and the binding of the antibody Fc region to cell receptors. This can trigger engulfment of the pathogen by phagocytes or lysis by killer cells. By oligonucleotide site-directed mutagenesis we have engineered a single amino acid change in a mouse IgG2b antibody (Glu 235----Leu) which now enables the antibody to bind to the FcRI (high affinity) receptor on human monocytes with a 100-fold improvement in affinity. This indicates that Leu 235 is a major determinant in the binding of antibody to FcRI and that the receptor may interact directly with the region linking the CH2 domain to the hinge. Tailoring the affinity of antibodies for cell receptors could help dissect their role in clearing pathogen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965792     DOI: 10.1038/332563a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  57 in total

Review 1.  C1q receptors.

Authors:  P Eggleton; A J Tenner; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 2.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

Review 3.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 4.  Function and heterogeneity of human Fc receptors for immunoglobulin G.

Authors:  J C Unkeless
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

6.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

7.  Expanding the Scope of Antibody Rebridging with New Pyridazinedione-TCO Constructs.

Authors:  Angela N Marquard; Jonathan C T Carlson; Ralph Weissleder
Journal:  Bioconjug Chem       Date:  2020-04-28       Impact factor: 4.774

8.  Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.

Authors:  E Rajnavölgyi; G Fazekas; J Lund; M Daeron; J L Teillaud; R Jefferis; W H Fridman; J Gergely
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

9.  Transferrin-antibody fusion proteins are effective in brain targeting.

Authors:  S U Shin; P Friden; M Moran; T Olson; Y S Kang; W M Pardridge; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains.

Authors:  H G Cheon; W J LaRochelle; D P Bottaro; W H Burgess; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.